Enbrel Price Cap Blocked: One Ruling That Could Reshape States Drug Pricing

Federal court blocks Colorado's 70% price cap on Enbrel — ruling could shut down state drug pricing laws nationwide. Plus: Casgevy label expansion to age 2 for SCD/TDT sends CRISPR Therapeutics surging 8%. Moderna mFLUSIVA rally hits 70% ahead of August 5 FDA decision. AstraZeneca-CSPC $1.7B kidney deal; Celea raises $180M for IPF; Orca Bio prices Tregzi at $428K.Visit us at www.thepharmcloseout.compharma, biotech, FDA, clinical trials, drug approvals, Enbrel, Amgen, drug pricing, Casgevy, CRISPR Therapeutics, Moderna, sickle cell disease